Russian nuclear monopoly Rosatom to expand into domestic pharma business

Russian nuclear monopoly Rosatom is expanding in the domestic pharmaceutical business through investing six billion roubles ($105 million) in the construction of a factory for the production of drugs for the treatment of cancer and autoimmune diseases, reports The Pharma Letter’s local correspondent.

The new factory will be built in the Moscow region. Implementation of the project will be carried out by Rosatom Healthcare, which is a specially established subsidiary of Rosatom.

Rosatom does not indicate the timing for the construction but, according to some sources close to the company, the project may be completed within the next four-to-five years.